Abstract: Described embodiments provide systems and methods for intelligent load balancing of hosted sessions. A processor can determine a plurality of metrics for each of a plurality of machines configured to connect client devices with hosted sessions. The processor can receive, from a client device, a request to establish a connection with one of the plurality of machines to access a hosted session. The processor can determine a score for each of the plurality of machines based at least on the plurality of metrics for each of the plurality of machines. The processor can select a machine from the plurality of machines as a function of the score and a resource cost of the machine. The processor can cause the client device to connect to the selected machine for the hosted session.

Abstract: The present invention includes nucleic acids, proteins, Chikungunya virus (CHIKV) Virus Like Particles (VLP), and methods of making a Chikungunya virus (CHIKV) Virus Like Particles (VLP) comprising: inserting one or more nucleic acids into a lentiviral backbone, wherein the nucleic acid encodes one or more Chikungunya virus (CHIKV) proteins; transfecting the one or more nucleic acids into the lentiviral backbone into a cell line; culturing the transfected cell line under conditions in which the Chikungunya virus (CHIKV) Virus Like Particles (VLP) are released from the cell line; and isolating the Chikungunya virus (CHIKV) Virus Like Particles (VLP) from a culture supernatant.

Abstract: The present invention includes compositions, methods, vectors, vaccines, cell lines and other constructs for making and used Zika virus Reporter Virus Particles (RVPs) and/or Virus Like Particles (VLPs) that are safe for handling and manufacturing and are able to generate an effective immune response against Zika virus and can be readily scaled up for cost-effective production.

Abstract: The present invention includes composition and methods for making multivalent vaccines for immunization against Flavivirus and/or arboviruses including a multivalent Virus Like Particles (VLP) and mixtures thereof, the method comprising: method of making a Flavivirus and/or arboviruses Virus Like Particles (VLP) comprising: inserting two or more nucleic acids that encode at least one Flavivirus protein into a lentiviral backbone vector; generating a lentivirus by transfecting a first cell line with the lentiviral backbone vector and isolating the lentivirus therefrom; transducing a second cell line with the lentivirus; culturing the transduced cell line under conditions in which the multivalent Flavivirus Virus Like Particles (VLP) are released from the cell line; and isolating the Flavivirus Virus Like Particles (VLP) from a culture supernatant, wherein a cell line makes a virus-specific VLP, and the VLPs are purified and then mixed in different combinations to make the multivalent vaccine.

Abstract: This invention relates to a method and a system for performing seamless authentication and identification of a mobile subscriber requesting to access a 3rd Party Merchant's online platform. The subscriber verification system intercepts a message sent from a first network node to a second network node during a data session establishment procedure. The subscriber verification system extracts a first set of identification values associated with a user equipment (UE) from the intercepted message. After the data session is established, the UE sends an encrypted request to access the Merchant server. The Merchant server identifies a second set of identification values associated with the encrypted request and sends them for validation to the subscriber verification system. The second set of identification values is compared against the first set of identification values. If the two set of identification values match, the UE is authenticated.

Abstract: Compounds with anti-viral properties are provided that are based on the following structures: A variety of heteroaromatic groups have been found to be biologically active against viral infections. In some embodiments, a dimeric compound is provided with each monomer linked by a repeating glycol linking group.

Abstract: Compounds with anti-viral properties are provided that are based on the following structures: A variety of heteroaromatic groups have been found to be biologically active against the Zika (ZIKV) virus. In some embodiments, a dimeric compound is provided with each monomer linked by a repeating glycol linking group.

Abstract: The present invention includes nucleic acids, proteins, Chikungunya virus (CHIKV) Virus Like Particles (VLP), and methods of making a Chikungunya virus (CHIKV) Virus Like Particles (VLP) comprising: inserting one or more nucleic acids into a lentiviral backbone, wherein the nucleic acid encodes one or more Chikungunya virus (CHIKV) proteins; transfecting the one or more nucleic acids into the lentiviral backbone into a cell line; culturing the transfected cell line under conditions in which the Chikungunya virus (CHIKV) Virus Like Particles (VLP) are released from the cell line; and isolating the Chikungunya virus (CHIKV) Virus Like Particles (VLP) from a culture supernatant.

Abstract: A system and method for routing LoRaWAN backend traffic between peer visited and home Network Server nodes to achieve global roaming in a scalable manner. A LoRaWAN Routing and Control System (LRCS) node is deployed between a visited Network Server and a home Network Server and is configured to proxy signaling and payload data messages therebetween. LRCS node can provide policy control, billing and rating based on roaming agreements between peer LoRaWAN roaming networks. LRCS node protects the overall network by discarding blacklisted and malicious traffic. LRCS node can enhance the message flow logic by adding routing information in the messages such that destination networks can identify that message is routed through a trustable source.

Abstract: The present invention includes compositions, methods, vectors, vaccines, cell lines and other constructs for making and used Zika virus Reporter Virus Particles (RVPs) and/or Virus Like Particles (VLPs) that are safe for handling and manufacturing and are able to generate an effective immune response against Zika virus and can be readily scaled up for cost-effective production.

Abstract: Aa gene therapy method comprises modifying at least one CD4 molecule to form CD4mod, marking target cells with immunomagnetic beads, and killing the marked target cells. The method comprises applying a first vector that expresses TK-SR39 and applying a second vector that expresses HIV Tat and a CRISPR-CCR5 cassette to knockout CCR5. The TK-SR39 rapidly kills cells in a presence of Ganciclovir.

Abstract: A virtualized Policy, Charging, Negotiation and Enforcement Entity (PCNE) is disclosed for serving cellular traffic across multiple networks. The PCNE manages signaling and user payloads to apply policies compliant to concerned networks in real time. The PCNE provides policy control to a Home network even when its outbound subscriber traffic is locally offloaded at a Visited network or IP Packet Exchange (IPX) cloud. The PCNE protects the Visited network against capacity overuse by inbound subscriber traffic, thereby providing joint control to the Home and Visited network operators resulting in optimal use of bandwidth and resources along with consistent subscriber experience. The PCNE enables the Home network operator to implement domestic quota buckets and policies while its subscriber is roaming in the Visited network by applying differential policy and charging rules. Traffic can be offloaded to a preferred packet data gateway after enforcing the negotiated policies.

Abstract: Compounds with anti-viral properties are provided that are based on the following structures: A variety of heteroaromatic groups have been found to be biologically active against the Zika (ZIKV) virus. In some embodiments, a dimeric compound is provided with each monomer linked by a repeating glycol linking group.

Abstract: A method, system, and apparatus for treating a patient with HIV. A vector can be modified from a thymidine kinase gene. The modified vector is expressed in the presence of tat RNA. The modified vector is then package and delivered to HIV-infected cells. The replication of HIV is inhibited by eliminating infected cells in the presence of Ganciclovir. Modified cells are then selected utilizing transient tat RNA transfection and GFP expression. Vector-modified stem cells are then selected for transplantation back into the patient, thereby producing a normal immune system in the patient when the modified vector remains dormant in the absence of HIV tat.

Abstract: A method and apparatus for validating the integrity of computer software installer files prior to installation of computer software comprising: generating at least one signature file for at least one corresponding installer file, the at least one signature file comprising a file name, a file size and a checksum, wherein the checksum is calculated for the corresponding installer file; and packaging the at least one signature file with the corresponding installer file, wherein the checksum in the signature file is used to validate the integrity of the installer file prior to installation of the installer file.

Abstract: A method and apparatus for validating the integrity of computer software installer files prior to installation of computer software comprising: generating at least one signature file for at least one corresponding installer file, the at least one signature file comprising a file name, a file size and a checksum, wherein the checksum is calculated for the corresponding installer file; and packaging the at least one signature file with the corresponding installer file, wherein the checksum in the signature file is used to validate the integrity of the installer file prior to installation of the installer file.